ArticleHaematologica2020
HIF-1α is over-expressed in leukemic cells from
Open access · goldAbstract read
In one paragraph
Article in Haematologica, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 39 papers.
0numbers the graph read from it
0cells of the map it votes in
39citing papers in PubMed
4.4field-weighted citation impact, top 5% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
39 citing papers in PubMed, 61 citations in OpenAlex.
- Hypoxia Inhibitor Improves Iodine Uptake Disorder in Thyroid Cancer Through the hsa_circ_0023990/miR-448/DNMT1/NIS Axis.Cancer science · 2025Article
- The Multifaceted Role of p53 in Cancer Molecular Biology: Insights for Precision Diagnosis and Therapeutic Breakthroughs.Biomolecules · 2025Review
- Telomeres, telomerase, and cancer: mechanisms, biomarkers, and therapeutics.Experimental hematology & oncology · 2025Review
- Targeting hypoxia-inducible factor 1α in chronic graft-versus-host disease to enhance graft-versus-leukemia responses: implications for nanotherapeutics.Frontiers in immunology · 2025Review
- Inflammation mediated angiogenesis in chronic lymphocytic leukemia.Annals of hematology · 2024Article
- MiR-155 deficiency and hypoxia results in metabolism switch in the leukemic B-cells.Cancer cell international · 2024Article
- Mutant TP53 promotes invasion of lung cancer cells by regulating desmoglein 3.Journal of cancer research and clinical oncology · 2024Article
- Regulation of Hypoxia Dependent Reprogramming of Cancer Metabolism: Role of HIF-1 and Its Potential Therapeutic Implications in Leukemia.Asian Pacific journal of cancer prevention : APJCP · 2024Review
- Article
- HIF-1α signaling: Essential roles in tumorigenesis and implications in targeted therapies.Genes & diseases · 2024Review
- Anti-tumor activity of selinexor in combination with antineoplastic agents in chronic lymphocytic leukemia.Scientific reports · 2023Article
- Indian journal of hematology & blood transfusion : an official journal of Indian Society of Hematology and Blood Transfusion · 2023Article
- Investigation into the Role of Long-Non-Coding RNANon-coding RNA · 2023Article
- Advances in hyperbaric oxygen to promote immunotherapy through modulation of the tumor microenvironment.Frontiers in oncology · 2023Review
- Distinct p53 phosphorylation patterns in chronic lymphocytic leukemia patients are reflected in the activation of circumjacent pathways upon DNA damage.Molecular oncology · 2023Article
- HIF-PH Encoded byPharmaceuticals (Basel, Switzerland) · 2022Article
- B-cell Receptor Signaling Induced Metabolic Alterations in Chronic Lymphocytic Leukemia Can Be Partially Bypassed byHemaSphere · 2022Article
- Action Sites and Clinical Application of HIF-1α Inhibitors.Molecules (Basel, Switzerland) · 2022Review
- Transition of autophagy and apoptosis in fibroblasts depends on dominant expression of HIF-1α or p53.Journal of Zhejiang University. Science. B · 2022Article
- The HIF-1α pathway plays a critical role in salivary gland development in ex vivo organ cultures.FEBS open bio · 2022Article
Corrections and comments
- Commented on by
Authors and funding
26 authors at 13 institutions in 2 countries.
Valentina GriggioDivision of Hematology, A.O.U. Città della Salute e della Scienza di Torino, Turin, Italy.
Candida VitaleDivision of Hematology, A.O.U. Città della Salute e della Scienza di Torino, Turin, Italy.
Maria TodaroDivision of Hematology, A.O.U. Città della Salute e della Scienza di Torino, Turin, Italy.
Chiara RigantiDepartment of Oncology, University of Turin, Turin, Italy.
Joanna KopeckaDepartment of Oncology, University of Turin, Turin, Italy.
Chiara SalvettiDivision of Hematology, A.O.U. Città della Salute e della Scienza di Torino, Turin, Italy.
Riccardo BombenClinical and Experimental Onco-Hematology Unit, CRO Aviano National Cancer Institute, Aviano, Italy.
Michele Dal BoClinical and Experimental Onco-Hematology Unit, CRO Aviano National Cancer Institute, Aviano, Italy.
Daniela MagliuloDivision of Experimental Oncology, IRCCS San Raffaele Scientific Institute, Milan, Italy.
Davide RossiDepartment of Hematology, Oncology Institute of Southern Switzerland and Institute of Oncology Research, Bellinzona, Switzerland.
Gabriele PozzatoDepartment of Internal Medicine and Hematology, Maggiore General Hospital, University of Trieste, Trieste, Italy.
Lisa BonelloDepartment of Molecular Biotechnology and Health Sciences, University of Turin, Turin, Italy.
Monia MarchettiHematology Day Service, Oncology SOC, Hospital Cardinal Massaia, Asti, Italy.
Paola OmedèDivision of Hematology, A.O.U. Città della Salute e della Scienza di Torino, Turin, Italy.
Ahad Ahmed KodipadDivision of Hematology, Department of Translational Medicine, University of Eastern Piedmont, Novara, Italy.
Luca LaurentiFondazione Policlinico Universitario Agostino Gemelli, Rome, Italy.
Giovanni Del PoetaDivision of Hematology, S. Eugenio Hospital and University of Tor Vergata, Rome, Italy.
Francesca Romana MauroHematology, Department of Translational and Precision Medicine, Sapienza University, Policlinico Umberto I, Rome, Italy.
Rosa BernardiDivision of Experimental Oncology, IRCCS San Raffaele Scientific Institute, Milan, Italy.
Thorsten ZenzDepartment of Medical Oncology and Hematology, University Hospital and University of Zurich, Zurich, Switzerland.
Valter GatteiClinical and Experimental Onco-Hematology Unit, CRO Aviano National Cancer Institute, Aviano, Italy.
Gianluca GaidanoDivision of Hematology, Department of Translational Medicine, University of Eastern Piedmont, Novara, Italy.
Robin FoàHematology, Department of Translational and Precision Medicine, Sapienza University, Policlinico Umberto I, Rome, Italy.
Massimo MassaiaHematology Unit, ASO Santa Croce e Carle, Cuneo, Italy.
Mario BoccadoroDivision of Hematology, A.O.U. Città della Salute e della Scienza di Torino, Turin, Italy.
Marta CosciaDivision of Hematology, A.O.U. Città della Salute e della Scienza di Torino, Turin, Italy marta.coscia@unito.it.
Azienda Ospedaliera Citta' della Salute e della Scienza di Torino · ITCentro di Riferimento Oncologico · ITUniversity of Turin · ITPoliclinico Umberto I · ITUniversità degli Studi del Piemonte Orientale “Amedeo Avogadro” · ITVita-Salute San Raffaele University · ITAgostino Gemelli University Polyclinic · ITAzienda Sanitaria Locale di Asti · ITAzienda Sanitaria Ospedaliera S.Croce e Carle Cuneo · ITInstitute of Oncology Research · CHSt. Eugenio Hospital · ITUniversity of Trieste · ITUniversity of Zurich · CH
Funding
No grant is acknowledged in the PubMed record.
Abstract
In chronic lymphocytic leukemia (CLL), the hypoxia-inducible factor 1 (HIF-1) regulates the response of tumor cells to hypoxia and their protective interactions with the leukemic microenvironment. In this study, we demonstrate that CLL cells from
Indexed as
Leukemia, Lymphocytic, Chronic, B-CellAnimalsHumansHypoxia-Inducible Factor 1, alpha SubunitMicePhosphatidylinositol 3-KinasesTumor MicroenvironmentTumor Suppressor Protein p53Von Hippel-Lindau Tumor Suppressor ProteinHypoxia-Inducible Factor 1, alpha SubunitPhosphatidylinositol 3-KinasesTP53 protein, humanTumor Suppressor Protein p53Von Hippel-Lindau Tumor Suppressor Protein
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY-NC
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.